Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Registration Number
- NCT00049751
- Lead Sponsor
- Abbott
- Brief Summary
The purpose of the study is to evaluate safety by collecting serious adverse events in subjects with moderately to severely active rheumatoid arthritis who are unable to obtain etanercept and who have failed one or more prior disease-modifying antirheumatic drugs (DMARDs).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 3000
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Change in disease activity score at visit week 12 as compared to baseline
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (53)
Thomas McGee, MD
🇺🇸Mobile, Alabama, United States
Desert Valley Medical
🇺🇸Apple Valley, California, United States
Kenneth Hsu, MD, Inc.
🇺🇸Bakersfield, California, United States
Rheumatology Clinic
🇺🇸Los Angeles, California, United States
Michael Harrington, MD
🇺🇸Napa, California, United States
Midori Jane Nishio, MD
🇺🇸Walnut Creek, California, United States
Naveen Raja, MD
🇺🇸Whittier,, California, United States
Mountain Rheumatology
🇺🇸Denver, Colorado, United States
Division of Rheumatic Diseases/University of CT Health Center
🇺🇸Farmington,, Connecticut, United States
New Haven Medical Group, PC
🇺🇸New Haven, Connecticut, United States
Scroll for more (43 remaining)Thomas McGee, MD🇺🇸Mobile, Alabama, United States